NCT03535493

The Effect of ACT and Float REST on Burnout Syndrome.

Terminated NA Last updated 29 August 2018

What this trial tests

NA trial testing Acceptance and Commitment Therapy (ACT) in Burnout Syndrome in 45 participants. Terminated before completion.

Timeline

1 June 2018

Primary endpoint
27 August 2018

27 August 2018

Quick facts

Lead sponsor	Amrinder Babbra
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	45
Start date	1 June 2018
Primary completion	27 August 2018
Estimated completion	27 August 2018
Sites	1 location across United States

Drugs / interventions tested

• Acceptance and Commitment Therapy (ACT)
• Float REST
• ACT + Float REST

Conditions studied

• Burnout Syndrome — all drugs for Burnout Syndrome →

Sponsor

Amrinder Babbra

Who can join

Eligibility, any sex, with Burnout Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In 1982, Steven Hayes, a clinical psychologist, developed Acceptance and Commitment Therapy (ACT), a unique empirically based psychological intervention that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies, to increase psychological flexibility. In 1954, John Lilly, a cognitive neuroscientist, developed the sensory deprivation tank (known today as Floatation Restricted Environmental Stimulation Therapy - Float REST), to access a wide range of healing, higher brain functions, and meditation through an unparalleled deep relaxation state. In this study, the investigators aim to examine whether participants in the ACT + Float REST condition will have larger decreases of the burnout phenomenon than those who receive either only ACT or Float REST.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.